NCT02665195

Prospective Registry of Multiplex Testing (PROMPT)

Prospective Registry of Multiplex Testing (PROMPT): Phase II

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 689 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study is being done to learn more about how changes in certain genes may be linked to cancer. Some people with cancer got their disease because they inherited an abnormal (mutated) gene. The researchers of this study want to better understand the risks that are linked to genetic changes in these less well-studied genes. By understanding these risks, we believe that doctors will be able to give better advice to families with mutations in these genes.

Detailed description

PROMPT (Prospective Registry of Multiplex Testing) is an Internet-based, patient-directed ascertainment study. It is a partnership between Memorial Sloan Kettering, University of Pennsylvania, Mayo Clinic, and Dana Farber Cancer Institute in collaboration with Ambry Genetics, GeneDx, Myriad Genetics, Pathway Genomics, and Quest Laboratories (5 laboratories providing multiplex panel testing commercially).

Conditions

• Genetic Testing

Interventions

Type	Name	Description
OTHER	saliva specimen
BEHAVIORAL	questionnaire

Timeline

• Start date: 2016-01-01
• Primary completion: 2027-01-01
• Completion: 2027-01-01
• First posted: 2016-01-27
• Last updated: 2026-02-09

Locations

10 sites across 1 country: United States